<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099082</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180175</org_study_id>
    <nct_id>NCT04099082</nct_id>
  </id_info>
  <brief_title>Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans</brief_title>
  <acronym>ALLOPIV</acronym>
  <official_title>Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchiolitis obliterans (BO) is the well-known manifestation of the chronic pulmonary
      graft-versus-host disease(GVHD) after allogeneic hematopoietic stem cell transplantation
      (HSCT). The pathophysiology of BO is, however, poorly known. The available data strongly
      support the role of respiratory viruses, in particular paramyxoviruses (parainfluenzae virus
      (PIV), respiratory syncytial virus, metapneumovirus). It is likely that the alloimmune
      response triggered by the respiratory virus is inadequate and leads to the peribronchiolar
      fibrotic process. The objective is to analyze the kinetics of profiles of the blood and
      respiratory host responses resulting from a high or low parainfluenza respiratory infection,
      in order to evaluate if the occurrence of a BO is associated with a specific signature We
      will evaluate the predictive signature of a BO after a parainfluenza virus infection by
      characterizing the differences between the patients evolving and those not evolving to a BO
      at 2 months after the infection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Host response transcriptomic signature in both blood and respiratory tract after PIV infection</measure>
    <time_frame>at the time of BO, through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Recipients</condition>
  <condition>Acute Respiratory Infection</condition>
  <condition>Parainfluenza Virus (PIV)</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>eligible patients with 10% decline in Forced Expiratory Volume (FEV1) at 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>eligible patients free of 10% FEV1 decline at 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>samples</intervention_name>
    <description>blood sample nasal swab</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples nasal swab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult recipients of allogeneic HSCT with PIV pulmonary infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult recipients of allogeneic HSCT

          -  Pulmonary infection with PIV

        Exclusion Criteria:

          -  No health care insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>A Bergeron-Lafaurie, MD PhD</last_name>
    <phone>33 1 42 49 49 49</phone>
    <email>anne.bergeron-lafaurie@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>S Cassonnet</last_name>
    <phone>43 1 42 49 49 49</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Louis</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Paramyxoviridae Infections</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

